Aktiia banks CHF 27 million to mitigate hypertension worldwide

Over 1.4 billion people worldwide are affected by high blood pressure, resulting in more than 18 million related deaths annually. This strategic infusion of capital will accelerate Aktiia's mission to ease the global burden of hypertension. Alongside Redalpine, Aktiia’s financing round also attracted an international investor syndicate including Khosla Ventures, Molten, Translink Capital, Verve, and 415 Capital. 

Built on 20+ years of research, Aktiia's artificial intelligence technology makes blood pressure data collection easier, offering personalized, continuous, and medical-grade blood pressure and heart rate data. Founded in 2018, Aktiia empowers people, researchers, and clinicians with unique blood pressure data paving the way for novel understanding and personalized patient care of hypertension.

With over 300 million data points from across the globe, Aktiia’s continuous blood pressure dataset is growing exponentially, creating countless opportunities for deep learning on public health trends and patterns to advance our understanding of blood pressure and provide predictive insights on a global scale. The CE-marked device is currently available in seven European markets and approved as a medical device in 44 countries worldwide, used by over 60,000 customers and dozens of healthcare organizations.